RIVASTIGMINE ZENTIVA 9.5 mg/24 hours, medicated transdermal patch 30 patches in individual sachets, CIP 3400930311127
Active ingredients: Rivastigmine
Commercialized according to BDPMDispensing in France: Prescription only
Medicated transdermal patch30 patches in individual sachets, CIP 3400930311127transdermique
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RIVASTIGMINE ZENTIVA 9,5 mg/24 heures, dispositif transdermique
- Pharmaceutical form
- dispositif
- Route of administration
- transdermique
- Presentation description
- 30 sachet(s) papier polytéréphtalate (PET) polyéthylène aluminium polyamide avec fermeture de sécurité enfant de 1 dispositif(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 17 Mar 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69978449CIP73031112CIP133400930311127Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIVASTIGMINE BASEdispositif | 13,8 mg · un dispositif | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.